The grades of eight Biotechnology stocks are on the rise this week on . Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
YM BioSciences (AMEX:) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. YM BioSciences is a drug development company, engages in advancing three clinical-stage hematology and cancer-related products. In Portfolio Grader’s specific subcategories of Earnings Revisions and Sales Growth, YMI also gets A’s. .
This week, Celsion (NASDAQ:) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Celsion is an innovative oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer. Shares of CLSN have increased 27.8% over the past month, better than the 4.7% increase the Nasdaq has seen over the same period of time. .
Synergy Pharmaceuticals (NASDAQ:) improves from a C to a B rating this week. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. Investors have pushed the stock price up 24.1% over the past month. .
The rating of GTx Inc. (NASDAQ:) moves up this week, rising from a C to a B. GTx discovers, develops, and commercializes therapeutics primarily related to the treatment of serious men’s health conditions. Wall Street seems to agree with the upgrade and has propelled the stock up 7.5% over the past month. .
NPS Pharmaceuticals
(NASDAQ:) is seeing ratings go up from a B last week to a A this week. NPS Pharmaceuticals is a biopharmaceutical company focused on the development of treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. .
Isis Pharmaceuticals (NASDAQ:) gets a higher grade this week, advancing from a C last week to a B. Isis Pharmaceuticals discovers and develops novel human therapeutic compounds. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 12.3% over the past month. .
Lexicon Pharmaceuticals’ (NASDAQ:) ratings are looking better this week, moving up to a B from last week’s C. Lexicon Pharmaceuticals researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. Wall Street has pushed the stock higher by 14.1% over the past month. .
Infinity Pharmaceuticals (NASDAQ:) earns a A this week, jumping up from last week’s grade of B. Infinity Pharmaceuticals researches and develops cancer drugs. Investors have pushed the stock price up 27.9% over the past month. .
Louis Navellier’s proprietary stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool .
